FDA Accepts Arcutis’ Application for ZORYVE® Cream to Treat Atopic Dermatitis in Infants

In a significant development for pediatric dermatology, Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for ZORYVE® (roflumilast) cream 0.05%. This application seeks to expand the treatment indication for mild to moderate atopic dermatitis to include infants aged 3 to 24 months. The FDA has set a target action date of February 23, 2027, under the Prescription Drug User Fee Act (PDUFA).

Atopic dermatitis, a common inflammatory skin condition, often presents in infancy, significantly impacting both the affected children and their families. The condition is characterized by intense itching and sleep disruptions, making it particularly burdensome for infants and challenging for caregivers. According to Lawrence F. Eichenfield, MD, a clinical investigator at Rady Children’s Hospital San Diego, there is a pressing need for effective and safe treatment options for this vulnerable population, especially given the limited FDA-approved therapies available.

Dr. Eichenfield noted, “ZORYVE cream 0.05% could provide clinicians and caregivers with an important new steroid-free treatment option that was specifically developed for infants and very young children.”

The sNDA submission is supported by promising data from two clinical trials: the Phase 2 open-label INTEGUMENT-INFANT study and a Phase 1 pharmacokinetic (PK) study. The INTEGUMENT-INFANT study involved 101 infants with mild to moderate atopic dermatitis, assessing the safety, tolerability, and exploratory efficacy of the ZORYVE cream over four weeks. Results indicated a favorable safety profile consistent with previous studies involving older children.

ZORYVE cream 0.05% is classified as a once-daily, steroid-free, non-greasy topical treatment. It is formulated without common irritants or sensitizing excipients, making it particularly suitable for young patients. Currently, ZORYVE is approved for treating mild to moderate atopic dermatitis in children aged 2-5 years.

Frank Watanabe, president and CEO of Arcutis, emphasized the importance of this new application, stating, “If approved, investigational ZORYVE cream 0.05% would be the first once-daily advanced targeted topical treatment for this especially vulnerable patient population.”

Atopic dermatitis is a prevalent condition, affecting approximately 9.6 million children in the United States alone. The chronic nature of the disease often begins during infancy, with symptoms that can lead to sleep disturbances and increased risk of skin infections. Pediatric atopic dermatitis presents unique challenges not only for the affected children but also for their families, underlining the necessity for effective management strategies.

The acceptance of Arcutis’ sNDA for ZORYVE cream represents a promising advance in the treatment landscape for atopic dermatitis, particularly for infants. If approved, this new indication could significantly enhance the quality of life for young patients and their families, providing a much-needed alternative to traditional steroid treatments. The forthcoming PDUFA date of February 23, 2027, marks a critical milestone for Arcutis Biotherapeutics as it seeks to address the urgent needs of this vulnerable patient population.